Other Clinical Trial - Effect of Mesenchymal Stem Cells(MSCs)

Status Recruiting

Clinical Trial Summary

This is a placebo controlled, randomized, double blinded study including Phase 1 and Phase 2. Phase I study is a safety assessment and Phase 2 study is incline to assess effectiveness of MSCs. Potential subjects must be screened and consented before enrolled. The primary objective of this study is to determine the effects of early intravenous infusion of allogeneic human umbilical cord mesenchymal stem cells (HucMSCs or MSCs used in the following section) for patients with acute ischemic stroke. Eligible patients will receive a single dose of MSCs or placebo within 24 hours after stroke. Patients will be followed for 2 years post infusion for safety and efficacy (change in neurological symptoms and quality of life). Assessments will occur during transplantation and at 3,7, 14 days and1,3, 6, 12, 18 and 24 months after infusions of stem cells.

Clinical Trial Description

In Phase 1 study, the eligible patients of acute cerebral infarction within 7 days after onset will be randomized to MSCs group or control group and receive intravenous MSCs 2 x 10^6/kg or placebo as a single dose, respectively. Each group will enroll 10 patients and patients will be followed for 2 years to observe the adverse events and evaluate the safety of MSCs for acute ischemic stroke patients. The safety and preliminary effectiveness of MSCs in the treatment of acute cerebral infarction will be summarized after all patients of Phase 1 study were followed for 3 months post infusion, and the report will be submit to the academic committee and the ethics committee to evaluate before approval to begin the Phase 2 study. In Phase 2 study, 100 patients with acute infarction within 24 hours after onset will be enrolled and randomized to MSCs group or control group. Patients will have baseline laboratory examinations and cerebral image (MRI or CTP). Enrolled patients will receive intravenous infusion of 2*10^6/kg MSCs or placebo for a single dose and follow for 24 months to assess the adverse events, neurological functional recovery and quality of life. ;

Study Design

Related Conditions & MeSH terms

Acute Stroke
Brain Infarction
Cerebral Infarction
Infarction
Infarction, Anterior Cerebral Artery
Infarction, Middle Cerebral Artery
Ischemic Stroke
Stroke
Stroke, Ischemic

Clinical Trial Details

NCT number	NCT04093336
Study type	Interventional
Source	Shanghai East Hospital
Contact	Gang Li, Doctor
Phone	0086-021-38804518-22106
Email	ligang@tongji.edu.cn
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	January 13, 2019
Completion date	December 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03993236` - Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke	Phase 4
Completed	`NCT04069767` - Innovative Physiotherapy in Stroke Rehabilitation	N/A
Recruiting	`NCT06342206` - The Assessment of Acute /Chronic Phase in Patients With Ischemic Cerebral Stroke Using TCM Diagnostic Tools
Recruiting	`NCT03605381` - MORbidity PRevalence Estimate In StrokE
Enrolling by invitation	`NCT04956211` - Periodontal Treatment and Ischemic Stroke	N/A
Active, not recruiting	`NCT05098236` - Effect of Visual Retraining on Visual Loss Following Visual Cortical Damage	N/A
Completed	`NCT03942588` - High-intensity Interval Training After Stroke	N/A
Recruiting	`NCT04949334` - Effects of Respiratory Muscle Training in Patients With Acute Ischemic Stroke	N/A
Terminated	`NCT04095767` - Assessing Safety and Performance of the ANA Catheter System, Combined With a Stent Retriever in Acute Ischemic Stroke	N/A
Not yet recruiting	`NCT06352086` - Understanding Visual Processing After Occipital Stroke
Withdrawn	`NCT04991038` - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients	N/A
Completed	`NCT01937182` - The Efficacy of Citalopram Treatment in Acute Stroke	Phase 2
Completed	`NCT03649295` - Combined Conventional Speech Therapy and Functional Electrical Stimulation in Dysphagia Following Stroke	N/A
Recruiting	`NCT05303649` - Effects of Neuronavigated Theta Burst Stimulation in Therapy of Post-stroke Aphasia	N/A
Completed	`NCT04233515` - Use of Oral Anticoagulants and Symptoms in Patients With Atrial Fibrillation in Örebro County
Completed	`NCT05102877` - Sensory Versus Motor Level Neuromuscular Electrical Stimulation	N/A
Completed	`NCT04089917` - A Study of the Use of the Q Aspiration Catheter to Remove Clot in Stroke Patients
Completed	`NCT05221112` - Effects of PNF Patterns Training on Trunk Balance, and Gait in Chronic Stroke Patients	N/A
Not yet recruiting	`NCT05035953` - Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke	Phase 2
Completed	`NCT06326801` - Resistive Diaphragmatic Breathing Exercise With Pursed Lips Breathing Exercise in Sub-acute Stroke Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of Mesenchymal Stem Cells(MSCs) Transplantation for Acute Cerebral Infarction Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms